Published in Invest New Drugs on November 01, 2006
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem (2007) 1.07
Chalcone-based inhibitors against hypoxia-inducible factor 1--structure activity relationship studies. Bioorg Med Chem Lett (2010) 0.75
A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. Oncotarget (2015) 0.75
Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res (1994) 3.00
An improved micro hematocrit method. Am J Clin Pathol (1954) 2.90
Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev (2003) 2.76
Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A (2002) 2.65
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res (2002) 2.06
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res (2000) 1.96
Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res (1997) 1.84
Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2002) 1.69
Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res (1999) 1.54
Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis (2000) 1.33
Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis. J Agric Food Chem (2003) 1.32
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 1.30
Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem (2000) 1.25
Effect of a propolis extract and caffeic acid phenethyl ester on formation of aberrant crypt foci and tumors in the rat colon. Fitoterapia (2002) 1.04
Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther (2003) 0.95
Beyond Herceptin and Gleevec. Curr Opin Chem Biol (2003) 0.94
Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice. Cancer Res (2001) 0.91
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer (2004) 0.89
The interaction of chalcones with tubulin. Anticancer Drug Des (2000) 0.86
Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin. Br J Cancer (2003) 0.80
Vioxx risk could signify trouble in class. Nat Rev Drug Discov (2004) 0.76
A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients. J Gastroenterol (2004) 0.75
Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia (2005) 4.61
Curcumin: the story so far. Eur J Cancer (2005) 4.17
The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes (1999) 3.30
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia (2010) 2.91
Structure and function of heparan sulphate proteoglycans. Biochem J (1986) 2.78
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res (2001) 2.69
Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat (2007) 2.58
Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. Diabetologia (2006) 2.53
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer (1999) 2.22
Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer (2005) 2.20
Gemcitabine--a major advance? Ann Oncol (1998) 2.05
Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer (2004) 1.97
Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab (2008) 1.95
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol (1997) 1.94
Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A (1996) 1.81
Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis. Diabetologia (2007) 1.73
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer (2000) 1.57
Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes (2001) 1.54
Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology (2005) 1.47
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer (2000) 1.43
Prognosis of isolated seizures in adult life. Br Med J (Clin Res Ed) (1981) 1.43
Latest trends in cancer incidence among UK South Asians in Leicester. Br J Cancer (2003) 1.42
Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer (2004) 1.40
Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab (2000) 1.38
The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer (2002) 1.33
Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. Diabetes (1998) 1.22
Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis. Am J Pathol (1995) 1.20
Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer (2005) 1.19
Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem (1995) 1.15
Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res (2001) 1.14
Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab (2000) 1.14
Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia (2009) 1.13
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer (2000) 1.12
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer (2006) 1.12
Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity. Br J Cancer (2003) 1.11
A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation. Biochem J (1998) 1.09
Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab (1996) 1.08
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer (2003) 1.08
Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic β-cells: protective role of p62-positive cytoplasmic inclusions. Cell Death Differ (2010) 1.07
3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem (1996) 1.07
Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer (2008) 1.07
Small heat shock proteins inhibit in vitro A beta(1-42) amyloidogenesis. FEBS Lett (1997) 1.07
Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis. Diabetes (1994) 1.07
Angiogenesis and non-small cell lung cancer. Lung Cancer (2000) 1.06
Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) (2011) 1.06
Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia (2006) 1.05
Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. J Clin Oncol (1999) 1.05
Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes (1996) 1.04
Islet amyloid polypeptide: a review of its biology and potential roles in the pathogenesis of diabetes mellitus. Vet Pathol (1993) 1.03
Identification of an extended N-acetylated sequence adjacent to the protein-linkage region of fibroblast heparan sulphate. Biochem J (1987) 1.03
Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia (1989) 1.03
Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol (2001) 1.02
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res (2001) 1.02
Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells. Carcinogenesis (2001) 1.00
Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. Blood (1996) 0.99
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer (2006) 0.98
Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention. Eur J Cancer (2003) 0.98
Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol (2001) 0.97
Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer (2000) 0.96
Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer (1989) 0.96
Increased vulnerability of newly forming beta cells to cytokine-induced cell death. Diabetologia (2005) 0.95
Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin Oncol (1998) 0.95
Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity. Br J Cancer (2004) 0.94
Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis. Br J Cancer (2007) 0.94
Assessment of insulin secretion in relatives of patients with type 2 (non-insulin-dependent) diabetes mellitus: evidence of early beta-cell dysfunction. Metabolism (2000) 0.94
Islet amyloid and islet amyloid polypeptide in cynomolgus macaques (Macaca fascicularis): an animal model of human non-insulin-dependent diabetes mellitus. Vet Pathol (1996) 0.94
Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol (1997) 0.94
Differences in attitudes between patients with primary colorectal cancer and patients with secondary colorectal cancer: is it reflected in their willingness to participate in drug trials? Eur J Cancer Care (Engl) (2005) 0.93
Phase I clinical trial of methylene dimethane sulfonate. Cancer Treat Rep (1987) 0.93
Phytoestrogens and xenoestrogens: the contribution of diet and environment to endocrine disruption. J Steroid Biochem Mol Biol (2007) 0.92
The mass, but not the frequency, of insulin secretory bursts in isolated human islets is entrained by oscillatory glucose exposure. Am J Physiol Endocrinol Metab (2005) 0.92
Beta cell nuclear musculoaponeurotic fibrosarcoma oncogene family A (MafA) is deficient in type 2 diabetes. Diabetologia (2012) 0.91
Effects of glucose ingestion versus infusion on pulsatile insulin secretion. The incretin effect is achieved by amplification of insulin secretory burst mass. Diabetes (1996) 0.90
In humans at least 75% of insulin secretion arises from punctuated insulin secretory bursts. Am J Physiol (1997) 0.90
A prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tract. Eur J Cancer Clin Oncol (1985) 0.90
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax (1999) 0.90
Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. Cancer (1985) 0.89
A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol (1984) 0.89
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer (2002) 0.89
Chondroitin sulphate proteoglycan production by NK cells and T cells: effects of xylosides on proliferation and cytotoxic function. Immunology (1988) 0.89
Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis (1994) 0.88
Relationship between fractional pancreatic beta cell area and fasting plasma glucose concentration in monkeys. Diabetologia (2009) 0.88
High-grade non-Hodgkin's lymphoma complicating polypoid nodular lymphoid hyperplasia and multiple lymphomatous polyposis of the intestine. Histopathology (1989) 0.88
A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology (2009) 0.88
Effects of somatostatin on pulsatile insulin secretion: elective inhibition of insulin burst mass. Am J Physiol (1996) 0.88
The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology (1999) 0.87
Pattern of postprandial carbohydrate metabolism and effects of portal and peripheral insulin delivery. Diabetes (1990) 0.87